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ABSTRACT  
 
Purpose : Pazopanib is active in soft tissue sarcoma (STS). Since pazopanib absorption is pH-
dependent, co-administration with gastric acid suppressive (GAS) agents such as proton pump 
inhibitors could affect exposure of pazopanib, and thereby its therapeutic effects. 
Experimental design : The EORTC 62043 and 62072 were single-arm phase II and placebo-
controlled phase III studies, respectively, of pazopanib in advanced STS. We first compared the 
outcome of patients treated with pazopanib with or without *$6DJHQWVIRURI treatment 
duration, and subsequently using various thresholds. The impact of concomitant GAS therapy 
was assessed on progression free survival (PFS) and overall survival (OS) using multivariate 
Cox models, exploring and comparing also the potential effect on placebo-treated patients. 
Results : Of 333 eligible patients, 59 (17.7%) received concomitant GAS therapy for >80% of 
pazopanib treatment duration. Median PFS was shorter in GAS therapy users versus no-users: 
2.8 vs. 4.6 months, respectively (HR=1.49 [95%CI 1.11-1.99], p=0.01). Concomitant 
administration of GAS therapy was also associated with a shorter median OS: 8.0 vs. 12.6 
months (HR=1.81 [95%CI 1.31-2.49], p<0.01). The longer the overlapping use of GAS agents 
and pazopanib, the worse the outcome with pazopanib. These effects were not observed in 
placebo-treated patients (HR=0.82 [95%CI 0.51-1.34, p=0.43] for PFS and HR=0.84 [95%CI 
0.48-1.48, p=0.54] for OS). 
Conclusions : Co-administration of long-term GAS therapy with pazopanib was associated with 
significantly shortened PFS and OS. Withdrawal of GAS agents must be considered whenever 
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possible. Therapeutic drug monitoring of pazopanib plasma concentrations may be helpful for 
patients on pazopanib and GAS therapy. 
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Translational relevance : (137 words) 
 
Pazopanib is approved for the treatment of advanced soft-tissue sarcoma (STS) pre-treated with 
doxorubicin-based regimens, based on an increase in progression-free survival, but not in overall 
survival (OS). 
From a pharmacological point of view, pazopanib absorption is pH-dependent, and co-
administration with gastric acid suppressive (GAS) agents (such as proton pump inhibitors) 
negatively affects pazopanib plasma concentrations. Herein, we investigated whether GAS 
agents could affect outcomes of STS patients treated with pazopanib in the EORTC phase II and 
III trials. 
We found that co-administration of long-term GAS therapy with pazopanib was associated with 
significantly shortened PFS and OS, possibly due to sub-optimal plasma concentrations. 
We conclude that withdrawal of GAS agents must be considered whenever possible in STS 
patients treated with pazopanib. Monitoring of pazopanib plasma concentrations may be helpful 
for patients on pazopanib and concomitant GAS therapy. 
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Introduction 
 
Although gastric acid suppressive (GAS) agents such as proton pump inhibitors (PPI) or 
histamine H2-receptor blockers (H2B) are used in 20̽50% of patients undergoing cancer 
treatment [1], the importance of gastric acid-mediated drug-drug interactions might be 
underestimated by medical oncologists and prescribing physicians.  
 
Because of the oral administration route of various molecular targeted therapies, including multi-
tyrosine kinase inhibitors (TKIs), drug±drug interactions concerning gastrointestinal absorption 
have become apparent [2]. Indeed, many TKIs show pH-dependent solubility in the 
physiologically relevant pH range, and their solubility might be decreased by the co-
administration of GAS agents, which increase gastric pH [3]. Such drug-drug interactions could 
reduce the systemic exposure of TKIs, resulting in sub-therapeutic exposure levels, and lead to 
loss of therapeutic benefit. [2, 4]. 
 
Pazopanib is an orally administered, potent TKI targeting the vascular endothelial growth factor 
receptors (VEGFR)-1, -2, and -3, platelet-derived growth factor receptors (PDGFR)-Įand ±ȕ
and KIT. It is approved for the treatment of patients with advanced non-adipocytic soft tissue 
sarcoma (STS) who have received prior chemotherapy for metastatic disease, based on the 
combined results of the EORTC 62072 (PALETTE) phase III and 62043 phase II trials [5, 6].  
 
The absorption of pazopanib is pH-dependent, and pazopanib is practically insoluble (<0.1 
mg/ml) at pH >4 [2].  In a post-marketing drug-drug interactions study investigating the effect of 
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increased gastric pH on the pharmacokinetics of pazopanib, pazopanib 800mg OD was given as 
monotherapy for 7 days followed by pazopanib 800mg OD in combination with the PPI 
esomeprazol 40mg OD for 5 consecutive days. The combined use of pazopanib and esomeprazol 
resulted in a decrease in the average maximum pazopanib plasma concentration and the average 
area under the concentration time curve 24 hours post-dose by 42% and 40%, respectively [7]. 
 
Retrospective data suggest that low plasma concentrations of pazopanib (through steady-state 
concentration < 20.5 µg/mL) are associated with poor outcomes in renal-cell carcinoma [8]. This 
was recently confirmed for renal cell cancer in terms of progression free survival (PFS), and a 
similar trend was observed in STS patients [9]. This means that a threshold for pazopanib 
activity likely exists for both tumor types.  
 
Based on this literature, we conducted a retrospective review of the EORTC 62043 and 62072 
databases, in order to investigate the association between the use of GAS therapy and clinical 
outcomes in STS patients treated with pazopanib. 
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Patients and methods 
 
Study design 
The present analysis combined the data from the completed trials EORTC phase II 62043 and 
phase III 62072 [5, 6]. Both studies were conducted in accordance with the declaration of 
Helsinki, after approval by institutional review boards, and written consent was obtained from all 
the subjects. 
A per protocol approach was adopted using the following patient inclusion criteria: i) patients 
eligible in their respective trial, ii) patients who did not have liposarcoma, due to their 
ineligibility for the phase III study based on the phase II results, iii) patients who started their 
allocated pazopanib treatment. 
 
Objectives and endpoints 
The main objective of the current analysis was to assess the potential presence of an association 
between the use of GAS agents during pazopanib administration and clinical outcomes. Primary 
and secondary endpoints were PFS and overall survival (OS), and were calculated from the date 
of registration/randomization to the first documentation of progression/death and the date of 
death, respectively. Patients alive at the time of clinical cut-off were censored at the date of last 
follow-up. 
 
GAS therapy embraced both PPI and histamine H2 blocking medications for which the 
considered drugs are listed in Supplementary Table 1. The percentage of the pazopanib 
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administration period during which there was an overlapping administration of GAS therapy was 
used to classify patients between users and non-users of GAS agents. Based on preparatory 
investigations, a threshold of 80% was selected upfront to differentiate between these patient 
groups. Exploratory analyses were performed to investigate the impact of this threshold choice 
on the estimated models. 
An additional objective was to examine whether co-administration of GAS therapy had an 
attenuating effect on pazopanib-specific toxicities such as hypertension, skin toxicities (alopecia, 
hypopigmentation, skin rash) or thyroid dysfunction. Definitions of these toxicities are detailed 
in the supplementary data. 
 
Statistical analysis 
Hazard ratios (HR) - with their associated 95% confidence intervals (CI) - were estimated from a 
multivariate Cox regression model adjusting for performance status (0 vs. 1), gender (male vs. 
female), tumor grade (low vs. intermediate vs. high) and age at randomization \UVYV!). 
The related 2-sided Logrank test p-value and Kaplan-Meier curves were displayed. In order to 
evaluate the real impact on the drug-drug interaction on the obtained results, similar analyses 
were conducted on placebo-treated patients from the phase III study, to discriminate for a false 
effect of GAS therapy on pazopanib treatment outcome, in addition of multivariate sensitivity 
analyses adjusting for GAS therapy administration at baseline as well. Analyses were performed 
using SAS, version 9.4 (SAS Institute Inc., Cary, NC, USA). 
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Results 
 
GAS therapy administration 
A total of 333 patients treated with pazopanib - 118 from the 62043 trial and 215 from the 62072 
trial - were eligible for this study. Median follow-up from registration/randomization was 27.6 
months (IQR: 22.9-35.4). Among them, 117 (35.1%) received GAS therapy at least once during 
their pazopanib treatment administration period and 59 (17.7%) of them concomitantly for >80% 
of the pazopanib duration (Table 1). Nineteen (5.7%) patients were already receiving GAS 
therapy at the time of registration. Patients baseline characteristics are depicted in Supplementary 
Table 2. 
 
Effect of concomitant use of pazopanib and GAS agents 
Two patients were excluded from multivariate analyses due to missing tumor grade status. As 
shown in Table 2, the concomitant administration of GAS therapy and pazopanib (>80% 
threshold) had a significant detrimental effect on PFS (HR=1.49, 95% CI 1.11-1.99, p-value 
0.008), with a median PFS of 2.8 months in GAS therapy users versus 4.6 months in non-users 
(Figure 1A). Male gender and higher tumor grade were associated with shorter PFS as well. 
From Figure 2, the risk of progression/death increased with the duration of GAS therapy taken 
concomitantly with pazopanib. By adjusting for the use of GAS therapy at baseline, the primary 
analysis was not significant at an >80% threshold but the observed trend remained (see 
supplementary Figure 1).  
Similarly, a significant negative effect of the concomitant administration of GAS therapy and 
pazopanib on OS was observed (HR=1.81, 95% CI 1.31-2.49, p-value <0.001), even with a low 
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threshold value (see Table 2 and Figure 1B and 2). A longer period of overlap of GAS DJHQWV¶ 
intake along with pazopanib administration has a detrimental effect on OS (Figure 2).  
 
Sensitivity analysis on Placebo-treated patients 
A total of 110 patients within the placebo-treated patients of the 62072 study were eligible for 
the sensitivity analyses. Among them, 33 (30%) received GAS therapy at least once during their 
pazopanib treatment administration period and 24 (21.8%) of them concomitantly for >80% of 
the pazopanib duration (Table 1). Median follow-up from registration/randomization for 
placebo-treated patients was 25.1 months (IQR: 22.7-28.9). Unlike the pazopanib-treated 
population, no association was observed between concomitant administration of GAS 
therapy/placebo and PFS (HR=0.82, 95% CI 0.51-1.34, p-value 0.43 for threshold >80%, Table 
3, Figure 1C and 2), as well as OS (HR=0.84, 95% CI 0.48-1.48, p-value 0.547 for threshold 
>80%, Table 3, Figure 1D and 2), ignorant of the threshold used. 
 
Impact on pazopanib-related toxicities 
No relevant differences in the frequency of pazopanib-related toxicities were observed between 
patients who received or did not receive GAS therapy concurrent with their pazopanib treatment 
(threshold >80%). Summary results of these analyses are presented in Supplementary Tables 3 
and 4. 
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Discussion 
 
The aim of this study was to investigate the potential effect of concomitant use of GAS therapy 
and pazopanib treatment on the clinical outcome of STS patients. For the primary analysis, we 
chose upfront to consider that a patient was a concomitant GAS therapy/pazopanib user if more 
than 80% of the pazopanib treatment administration period overlapped with GAS therapy 
prescriptions. This threshold included enough patients in each group (user vs non-user) to 
estimate any possible association. Chu et al 2016 [10] chose a threshold value of 20% to 
determine PPI-treated patients, while another study by Sun et al 2016 [11] considered the 
presence of concomitant administration when the patient received at least one PPI prescription 
together with capecitabine. However, a higher threshold value allowed the composition of a 
more homogeneous group of GAS users, making the occurrence of the expected drug-drug 
interaction with pazopanib more likely and therefore its potential impact on patient outcome. 
Moreover, the exploration of the impact of different threshold values on the outcome for 
concomitant administration neutralized the limitations of a single 80% value choice. 
From multivariate analyses, this co-administration of GAS therapy was found to have a negative 
impact on PFS and OS, for which the severity depended on the period of overlap of GAS agent 
intake with pazopanib; a longer duration led to a worse prognosis. Furthermore, these effects 
were not observed in the 62072 trial placebo cohort when using the same analytic approach, 
which confirmed that the detected impact on clinical outcomes was most likely caused by the 
drug-drug interaction between GAS therapy and pazopanib. 
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We consider that the effects of GAS therapy on the pharmacokinetics of pazopanib could 
account for this observation. Indeed pazopanib has a pH-dependent absorption and is practically 
insoluble (<0.1 mg/ml) at pH >4 [2]. As a consequence, the increase in gastric pH caused by 
GAS therapy could decrease pazopanib solubility and absorption, leading to sub-optimal plasma 
concentrations [3].  
 
Similar findings were reported in the PAZOGIST trial, a randomized phase 2 study of pazopanib 
in patients with advanced GIST [12]. In this trial, patients with a past history of gastrectomy had 
significantly lower plasma concentrations compared to patients without gastrectomy, and shorter 
PFS. 
 
A possible negative clinical effect of GAS agents on treatment outcomes has also been suggested 
for other oral anticancer agents with pH-dependent absorption: erlotinib in NSCLC, sunitinib in 
renal-cell carcinoma, and capecitabine in gastro-esophageal cancer [13, 10, 14]. Moreover, a 
recent study reported that the concomitant administration of PPIs and capecitabine is associated 
with an increased risk of recurrence in early stage colorectal cancer patients [11]. All studies 
conducted on this particular topic recommend avoiding GAS therapy concomitantly with 
anticancer treatments whenever possible.  
Of note, the circadian pattern of gastric pH and the time course during which medications that 
increase gastric pH have their effect, suggest that timing of pazopanib administration could 
influence the pazopanib exposure [15]. Therefore, if the concurrentuse of a GAS agent is 
medically necessary during pazopanib treatment, it is currently recommended that the dose of 
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pazopanib should be taken without food, once daily in the evening, concomitantly with the GAS 
agent.  
As administration of GAS therapy during pazopanib treatment reduced pazopanib efficacy, we 
undertook an exploratory analysis to assess whether co-administration also had a protective 
effect against pazopanib-specific toxicities such as hypertension, skin-related toxicities or 
thyroid dysfunction. In the corresponding analyses shown in the appendix, no consistent 
differences in occurrence of pazopanib-related toxicities were observed between concomitant 
GAS-users and non-users. Only slight distinctions were reported around skin toxicities but this 
analysis was further limited by the low overall incidence of adverse events. 
 
As in previous research on this topic, our study has some limitations [16]. First of all, the 
retrospective nature of the present study did not permit investigation of the respective timings of 
administration of GAS therapy and pazopanib. In addition, PPI dose and type of PPI was not 
considered in this study. As the potential to suppress the acidity of the stomach differs for the 
different PPI variants, this could be of relevance [17]. Also, it is unknown whether patients have 
always mentioned their over-the-counter use of GAS therapy given its widespread availability 
without prescription. Regarding GAS therapy itself, sub-group analyses differentiating PPIs from 
H2 blocker intake concomitantly to pazopanib were conducted, and a similar impact was 
observed on patient outcomes for both agents. 
As far as pazopanib plasma concentrations are concerned, it has been argued that clinical activity 
was lower in patients with trough steady-state concentrations < 20.5 µg/mL [8, 9]. In the context 
of medically necessary GAS therapy, we suggest that therapeutic drug monitoring could help 
detect patients with sub-optimal plasma exposure. Whether intra-patient pazopanib dose 
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escalation would improve outcomes in these patients remains unknown, although a recent study 
has shown the feasibility of such an approach [18]. Furthermore, acidic beverages increase the 
bioavailability of erlotinib - another TKI with pH-dependent absorption - [19]  but the impact in 
patients taking pazopanib with GAS therapy is currently unknown.  Another approach to prevent 
suboptimal pazopanib exposure could be to use alternative schedules to combine TKI and GAS. 
This is currently under investigation in at least two clinical trials with TKIs: regorafenib and 
afatinib (see www.clinicaltrials.gov: NCT02800330 and www.trialregister.nl: NTR6652, 
respectively, last accessed on Feb 20th, 2018).   
 
One of the main challenges for this study was the approach used to describe this particular type 
of drug-drug interaction effect. To handle the potential time-dependence relation of the drug, 
several methods such as landmark analyses, cox models with time-dependent covariates or even 
landmark supermodels [20] could be used. However, the relatively low number of patients and 
the complexity of our data made the results not applicable to these models. Moreover, by 
examining the patient profiles, no apparent link between patterns of GAS therapy administration 
and the duration of pazopanib treatment was identified, suggesting no specific trend over time. 
Therefore we preferred to preserve the assumption that the hazard functions are proportional 
over time and consider the level of co-administration as baseline information, even though this 
was conceptually inaccurate. Dichotomizing patients between user and non-users was the most 
intelligible way to illustrate the drug interaction impact. The proportion of concomitant GAS 
therapy/pazopanib expressed as a continuous covariate has been investigated too, showing a non-
significant detrimental effect on PFS (HR=1.04, 95% CI 0.98-1.10, p-value 0.219 for a +20% 
overlapping augmentation). 
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In conclusion, in the EORTC 62043 and 62072 trials, 35% of eligible patients took GAS agents 
at any time during pazopanib treatment, and in half of these patients for over 80% of the duration 
of their pazopanib treatment. Administration of long duration GAS therapy with pazopanib was 
associated with both shortened PFS and OS. Therefore, in patients with an indication to start 
pazopanib, withdrawal of GAS agents must be considered whenever possible, and patients 
should be warned against taking over the counter GAS medications. If patients have good 
medical reasons to stay on, or to start, GAS medication, therapeutic drug monitoring of 
pazopanib plasma concentrations could be helpful to optimally adjust the pazopanib dose.  
 
  
16 
 
5HIHUHQFHV 
 
[1]  G. Smelick, T. Heffron, L. Chu, B. Dean, D. West, S. Duvall, B. Lum, N. Budha, S. Holden, L. 
Benet, A. Frymoyer, M. Dresser and J. Ware, "Prevalence of acid-reducing agents (ARA) in cancer 
populations and ARA drug-drug interaction potential for molecular targeted agents in clinical 
development," Mol Pharm., vol. 10, no. 11, pp. 4055-62, 2013.  
[2]  N. Budha, A. Frymoyer, G. Smelick, J. Jin, M. Yago, M. Dresser, S. Holden, L. Benet and J. Ware, 
"Drug absorption interactions between oral targeted anticancer agents and PPIs: is pH-dependent 
solubility the Achilles heel of targeted therapy?," Clin Pharmacol Ther., vol. 92, no. 2, pp. 203-13, 
2012.  
[3]  R. van Leeuwen, F. Jansman, N. Hunfeld, R. Peric, A. Reyners, A. Imholz, J. Brouwers, J. Aerts, T. 
van Gelder and R. Mathijssen, "Tyrosine Kinase Inhibitors and Proton Pump Inhibitors: An 
evaluation of Treatment Options," Clin Pharmacokinet., vol. 56, no. 7, pp. 683-688, 2017.  
[4]  R. van Leeuwen, T. van Gelder, R. Mathijssen and F. Jansman, "Drug-drug interactions with 
tyrosine-kinase inhibitors: a clinical perspective.," Lancet Oncol., vol. 15, no. 8, pp. 315-26, 2014.  
[5]  W. van der Graaf, J. Blay, S. Chawla, D. Kim, B. Bui-Nguyen, P. Casali, P. Schöffski, M. Aglietta, 
A. Staddon, Y. Beppu, A. Le Cesne, H. Gelderblom, I. Judson, N. Araki, M. Ouali, S. Marréaud, R. 
Hodge, M. Dewji, C. Coens, G. Demetri, C. Fletcher, A. Dei Tos, P. Hohenberger, EORTC Soft 
Tissue and Bone Sarcoma Group and PALETTE study group, "Pazopanib for metastatic soft-tissue 
sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.," Lancet, vol. 
379, no. 9829, pp. 1879-86, 2012.  
[6]  S. Sleijfer, I. Ray-Coquard, Z. Papai, A. Le Cesne, M. Scurr, P. Schöffski, F. Collin, L. Pandite, S. 
Marréaud, A. De Brauwer, M. van Glabbeke, J. Verweij and J. Blay, "Pazopanib, a multikinase 
angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase 
II study from the European organisation for research and treatment of cancer-soft tissue and bone 
sarcoma group (EORTC study 620," J Clin Oncol., vol. 27, no. 19, pp. 3126-32, 2009.  
[7]  A. Tan, D. Gibbon, M. Stein, D. Lindquist, J. Edenfield, J. Martin, C. Gregory, A. Suttle, H. Tada, J. 
Botbyl and J. Stephenson, "Effects of ketoconazole and esomeprazole on the pharmacokinetics of 
pazopanib in patients with solid tumors.," Cancer Chemother Pharmacol., vol. 71, no. 6, pp. 1635-
43, 2013.  
[8]  A. Suttle, H. Ball, M. Molimard, T. Hutson, C. Carpenter, D. Rajagopalan, Y. Lin, S. Swann, R. 
Amado and L. Pandite, "Relationships between pazopanib exposure and clinical safety and efficacy 
in patients with advanced renal cell carcinoma.," Br J Cancer., vol. 111, no. 10, pp. 1909-16, 2014.  
[9]  R. Verheijen, L. Swart, J. Beijnen, J. Schellens, A. Huitema and N. Steeghs, "Exposure-survival 
analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose 
optimization.," Cancer Chemother Pharmacol., 2017.  
[10] M. Chu, J. Hecht, D. Slamon, Z. Wainberg, Y. Bang, P. Hoff, A. Sobrero, S. Qin, K. Afenjar, V. 
Houe, K. King, S. Koski, K. Mulder, J. Hiller, A. Scarfe, J. Spratlin, Y. Huang, S. Khan-Wasti, N. 
Chua and M. Sawyer, "Association of Proton Pump Inhibitors and Capecitabine Efficacy in 
Advanced Gastroesophageal Cancer: Secondary Analysis of the TRIO-13/LOGiC Randomized 
Clinical Trial.," JAMA Oncol., 2016.  
[11] J. Sun, A. Ilich, C. Kim, G. Wong, S. Ghosh, M. Danilak, K. Mulder, J. Spratlin, C. Chambers and 
M. Sawyer, "Concomitant Administration of Proton Pump Inhibitors and Capecitabine is Associated 
With Increased Recurrence Risk in Early Stage Colorectal Cancer Patients.," Clin Colorectal 
Cancer., vol. 15, no. 3, pp. 257-63, 2016.  
[12] O. Mir, C. Cropet, M. Toulmonde, A. Le Cesne, M. Molimard, E. Bompas, P. Cassier, I. Ray-
Coquard, M. Rios, A. Adenis, A. Italiano, O. Bouché, E. Chauzit, F. Duffaud, F. Bertucci, N. 
17 
 
Isambert, J. Gautier, J. Blay and D. Pérol, "PAZOGIST study group of the French Sarcoma Groupe-
Groupe d'Etude des Tumeurs Osseuses (GSF-GETO).. Pazopanib plus best supportive care versus 
best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and 
sunitinib (PAZO," Lancet Oncol., vol. 17, no. 5, pp. 632-41, 2016.  
[13] M. Chu, S. Ghosh, C. Chambers, N. Basappa, C. Butts, Q. Chu, D. Fenton, A. Joy, R. Sangha, M. 
Smylie and M. Sawyer, "Gastric Acid suppression is associated with decreased erlotinib efficacy in 
non-small-cell lung cancer.," Clin Lung Cancer, vol. 16, no. 1, pp. 33-9, 2015.  
[14] V. Ha, M. Ngo, M. Chu, S. Ghosh, M. Sawyer and C. Chambers, "Does gastric acid suppression 
affect sunitinib efficacy in patients with advanced or metastatic renal cell cancer?," J Oncol Pharm 
Pract., vol. 21, no. 3, pp. 194-200, 2015.  
[15] N. Hunfeld, D. Touw, R. Mathot, P. Mulder, R. VAN Schaik, E. Kuipers, J. Kooiman and W. Geus, 
"A comparison of the acid-inhibitory effects of esomeprazole and pantoprazole in relation to 
pharmacokinetics and CYP2C19 polymorphism.," Aliment Pharmacol Ther., vol. 31, no. 1, pp. 150-
9, 2010.  
[16] K. Hussaarts, R. van Leeuwen and R. Mathijssen, "Factors Affecting the Association of Proton Pump 
Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer.," JAMA Oncol., 2017.  
[17] K. Röhss, T. Lind and C. Wilder-Smith, "Esomeprazole 40 mg provides more effective intragastric 
acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg 
in patients with gastro-oesophageal reflux symptoms.," Eur J Clin Pharmacol., vol. 60, no. 8, pp. 
531-9, 2004.  
[18] R. Verheijen, S. Bins, R. Mathijssen, M. Lolkema, L. van Doorn, J. Schellens, J. Beijnen, M. 
Langenberg, A. Huitema, N. Steeghs and Dutch Pharmacology Oncology Group, "Individualized 
Pazopanib Dosing: A Prospective Feasibility Study in Cancer Patients.," Clin Cancer Res., vol. 22, 
no. 23, pp. 5738-46, 2016.  
[19] R. van Leeuwen, R. Peric, K. Hussaarts, E. Kienhuis, N. IJzerman, P. de Bruijn, C. van der Leest, H. 
Codrington, J. Kloover, B. van der Holt, J. Aerts, T. van Gelder and R. Mathijssen, "Influence of the 
Acidic Beverage Cola on the Absorption of Erlotinib in Patients With Non-Small-Cell Lung 
Cancer.," J Clin Oncol., vol. 34, no. 12, pp. 1309-14, 2016.  
[20] H. van Houwelingen and H. Putter, Dynamic Prediction in Clinical Survival Analysis, 2011.  
[21] H. Kletzl, M. Giraudon, P. Ducray, M. Abt, M. Hamilton and B. Lum, "Effect of gastric pH on 
erlotinib pharmacokinetics in healthy individuals: omeprazole and ranitidine.," Anticancer Drugs, 
vol. 26, no. 5, pp. 565-72, 2015.  
 
 
)LJXUHVOHJHQGV 
 
Figure 1: Progression-free survival (PFS) and overall survival (OS) in concomitant GAS therapy/administered 
treatment users (blue curve) versus non-users (red curve) at a threshold of 80%. PFS in pazopanib-treated population 
(A), OS in pazopanib-treated population (B), PFS in placebo-treated population (C) and OS in placebo-treated 
population (D). 
 
 
Pazopanib-treated population: Median PFS =  2.8 months (users) vs. 4.6 months (non-users); 
Median OS =  8.0 months (users) vs. 12.6 months (non-users). Placebo-treated population: 
Median PFS =  2.1 months (users) vs. 1.3 months (non-users); Median OS =  10.1 months 
(users) vs. 10.7 months (non-users) 
 
 
 
 
Figure 2: Evolution of the Hazard Ratio (multivariate analysis) for the effect of concomitant administration of GAS 
therapy/treatment on progression-free survival (top) and overall survival (bottom) among pazopanib (red) and 
placebo (blue) patients according to the selected threshold value 
 
Abbreviations: HR, Hazard ratio; CI, Confidence interval. Treatment: Pazopanib or Placebo 
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Table 1: Description of GAS therapy received together with protocol treatment in EORTC 62043 and 62072 studies. 
 
 
Population on pazopanib 
Population on 
placebo 
62043 
(N=118) 
62072 
(N=215) 
Total 
(N=333) 
Total 
(N=110) 
N (%)  N (%) N (%) N (%) 
Use of GAS therapy together with treatment                                                                         
 No GAS therapy                 85 (72.0)            131 (60.9)          216 (64.9)                          75 (68.2)             
 GAS therapy              33 (28.0) 84 (39.1) 117 (35.1) 35 (31.8) 
  PPI                       31 (26.3)             63 (28.4)   93 (27.9)                           26 (23.6)             
  H2 blocker                       1 (0.8)                19 (8.8)               21 (6.3)             8 (7.3)                 
  PPI & H2 blocker                 1 (0.8)                 2 (0.9)                 3 (0.9)              1 (0.9)                 
Proportion of treatment duration with concomitant 
administration of GAS therapy  
    
 No concomitant administration    85 (72.0)            131 (60.9)           216 (64.9)                            75 (68.2)                          
 0% < . <= 20%                               7 (5.9)                23 (10.7)             30 (9.0)                5 (4.5)             
 20% < . <= 40%                              1 (0.8)                 7 (3.3)                 8 (2.4)                 3 (2.7)             
 40% < . <= 60%                              3 (2.5)                 3 (1.4)                 6 (1.8)                 2 (1.8)             
 60% < . <= 80%                              6 (5.1)                 8 (3.7)                14 (4.2)                1 (0.9)             
 80% < .                                    16 (13.6)             43 (20.0)             59 (17.7)                          24 (21.8)                          
Abbreviations: GAS, gastric acid suppressive; PPI, proton pump inhibitor; H2B, Histamine H2 
blocker. 
 
Table 2: Association between clinical outcomes (PFS/OS) and baseline characteristics/concomitant GAS therapy administration (multivariate cox models) among pazopanib-treated 
patients. 
 
 
Population on pazopanib Multivariate Cox 
model for PFS 
Multivariate Cox 
model for OS 
Covariates 
Patients* 
(N=331) 
Observed 
PFS events 
(O=320) 
Observed 
OS events 
(O=262) 
Hazard Ratio 
(95% CI) Wald p-value 
Hazard Ratio 
(95% CI) 
Wald p-
value 
Concomitant 
administration of GAS 
therapy/Pazopanib 
No   273 (82.5)         264 (82.5)           212 (80.9)         1.00               
0.008 
1.00               
<0.001 
Yes    58 (17.5)          56 (17.5)             50 (19.1)          1.49 (1.11, 1.99) 1.81 (1.31, 2.49) 
Performance status 
0   167 (50.5)         161 (50.3)           124 (47.3)         1.00               
0.139 
1.00               
<0.001 
1   164 (49.5)         159 (49.7)           138 (52.7)         1.18 (0.95, 1.48) 1.73 (1.35, 2.22) 
Gender 
Male   139 (42.0)         136 (42.5)           117 (44.7)         1.00               
0.006 
1.00               
0.002 
Female   192 (58.0)         184 (57.5)           145 (55.3)         0.73 (0.58, 0.91)            0.68 (0.53, 0.87) 
Tumor grade 
Low    28 (8.5)            23 (7.2)               16 (6.1)            1.00               
<0.001 
1.00               
0.001 Intermediate   109 (32.9)         107 (33.4)            88 (33.6)          1.82 (1.16, 2.88) 2.31 (1.38, 3.89) 
High   194 (58.6)         190 (59.4)           158 (60.3)         2.33 (1.49, 3.63) 1.66 (0.97, 2.84) 
Age at randomization 
\HDUV   133 (40.2)         126 (39.4)           103 (39.3)         1.00               
0.414 
1.00               
0.623 
>50 years   198 (59.8)         194 (60.6)           159 (60.7)         1.10 (0.87, 1.39)           1.07 (0.82, 1.38) 
*: 2 patients are excluded from because of missing tumor grade 
Abbreviations: GAS, gastric acid suppressive; PFS, progression-free survival; OS, overall survival. CI, Confidence Interval 
 
Table 3: Association between clinical outcomes (PFS/OS) and baseline characteristics/concomitant GAS therapy administration (multivariate cox models) among placebo-treated 
patients. 
 
 
Population on placebo Multivariate Cox 
model for PFS 
Multivariate Cox 
model for OS 
Covariates 
Patients 
(N=110) 
Observed 
PFS events 
(O=110) 
Observed 
OS events 
(O=84) 
Hazard Ratio 
(95% CI) Wald p-value 
Hazard Ratio 
(95% CI) 
Wald p-
value 
Concomitant 
administration of GAS 
therapy/Placebo 
No    86 (78.2)          86 (78.2)             67 (79.8)          1.00               
0.4302 
1.00               
0.547 
Yes    24 (21.8)          24 (21.8)             17 (20.2)          0.82 (0.51; 1.34) 0.84 (0.48, 1.48) 
Performance status 
0    52 (47.3)          52 (47.3)             37 (44.0)          1.00               
0.0784 
1.00      
0.056 
1    58 (52.7)          58 (52.7)             47 (56.0)          1.43 (0.96; 2.12) 1.54 (0.99, 2.40) 
Gender 
Male    45 (40.9)          45 (40.9)             35 (41.7)          1.00               
0.5801 
1.00               
0.532 
Female    65 (59.1)          65 (59.1)             49 (58.3)          0.89 (0.58; 1.35) 0.86 (0.55, 1.36) 
Tumor grade 
Low     3 (2.7)             3 (2.7)                 2 (2.4)             1.00               
0.1481 
1.00           
0.238 Intermediate    26 (23.6)          26 (23.6)             18 (21.4)          2.93 (0.77; 11.07) 2.27 (0.54, 9.56) 
High    81 (73.6)          81 (73.6)             64 (76.2)          3.29 (0.96; 11.31) 1.55 (0.34, 7.05) 
Age at randomization 
\HDUV    54 (49.1)          54 (49.1)             38 (45.2)          1.00               
0.8242 
1.00               
0.124 
>50 years    56 (50.9)          56 (50.9)             46 (54.8)          0.96 (0.65; 1.41) 1.42 (0.91, 2.24) 
Abbreviations: GAS, gastric acid suppressive; PFS, progression-free survival; OS, overall survival. CI, Confidence Interval 
 
